---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-036150"
form_type: "8-K"
ticker: null
cik: "0001971543"
company_name: "Mural Oncology plc"
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T08:09:30.036559+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mural Oncology Q4 net loss $59.5M, cash $270.9M; nemvaleukin trials on track for 1H 2025 readouts

## Summary
- Net loss of $59.5M for Q4 2023 includes $15.2M non-cash share-based compensation, mostly one-time spin-out charges.
- Cash and equivalents $270.9M; cash runway projected into Q4 2025.
- Phase 2 ARTISTRY-6 mucosal melanoma cohort (potentially registrational) top-line data expected 1H 2025.
- New recommended phase 2 dose for LFIV dosing (30 µg/kg) to be evaluated in ARTISTRY-6 cohort 3.
- Company intends to nominate development candidates for engineered IL-18 and IL-12 therapies in 2024.

## SEC filing metadata
- accession: 0000950170-24-036150
- form_type: 8-K
- cik: 0001971543
- company_name: Mural Oncology plc
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971543/000095017024036150/0000950170-24-036150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971543/000095017024036150/mura-20240326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-036150
- JSON: https://secwatch.observer/filing/0000950170-24-036150.json
- Plain text: https://secwatch.observer/filing/0000950170-24-036150.txt

## Key facts
- Earnings Releases
  Mural Oncology plc reported the fourth quarter ended December 31, 2023 results: net income Net loss was $59.5 million for the fourth quarter of 2023.. Guidance reaffirmed.
  - Period: the fourth quarter ended December 31, 2023
  - Net income: Net loss was $59.5 million for the fourth quarter of 2023.
  - Guidance: reaffirmed
  - Result: reported results
  source text: Net loss was $59.5 million for the fourth quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971543/000095017024036150/0000950170-24-036150-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.